CD24 Tumor-Initiating Cell as a Novel Therapeutic Target in Myeloma
Abstract
Multiple Myeloma (MM) is a blood cancer of the B cell lineage characterized by monoclonal plasma cells. Most patients initially respond to the therapy but majority of them relapse and become refractory to treatment. These myeloma cells, which escape current modes of therapy. We name it tumor-initiating cells (TICs) in myeloma. Understanding the nature of myeloma-TICs will provide an opportunity to cure this disease by preventing its relapse. Through a systematical screening, our studies presented here demonstrated that CD24plus myeloma cells maintain the features of self-renewal and drug resistance in myeloma. We predict that anti-CD24 antibody may eliminate myeloma tumor initiating cells resulting in cure of myeloma disease or significant extension of patient survival.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2022
- Accession Number
- AD1190650
Entities
People
- Gail A Bishop
Organizations
- University of Iowa